Objective:

To explore the concept of dropless cataract surgery and its potential benefits, including reduced reliance on patient-administered drops and improved surgical outcomes.

Key Findings:

• Subconjunctival triamcinolone effectively controls postoperative inflammation and macular edema, comparable to topical steroids, suggesting a shift in postoperative management.
• Injection-based regimens show similar or lower rates of complications compared to traditional drop therapy, indicating a safer alternative.
• The approach allows for flexibility in postoperative treatment, accommodating individual patient needs.

Interpretation:

Dropless cataract surgery enhances reliability in postoperative care by minimizing patient dependency on medication adherence, thus improving overall surgical outcomes.

Limitations:

• Persistence of depot steroids can lead to increased intraocular pressure, particularly in patients with pre-existing glaucoma; monitoring and management strategies should be discussed.
• The visible subconjunctival depot may be surprising to patients if not properly explained; clear communication is essential.

Conclusion:

Dropless cataract surgery represents a significant advancement in cataract care, enhancing consistency and reducing uncertainty in postoperative management, ultimately leading to better patient outcomes.